TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DETECTNET

COPPER CU-64 DOTATATE Positron Emitting Activity
Oncology Approved 2020-09-03
1
Indication
--
Phase 3 Trials
1
Priority Reviews
5
Years on Market

Details

Status
Prescription
First Approved
2020-09-03
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: COPPER CU-64 DOTATATE

DETECTNET Approval History

Loading approval history...

What DETECTNET Treats

1 indications

DETECTNET is approved for 1 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Neuroendocrine Tumors
Source: FDA Label
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DETECTNET FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. Detectnet is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.

DETECTNET Patents & Exclusivity

Latest Patent: Sep 2041
Exclusivity: Sep 2027

Patents (4 active)

US12102696 Expires Sep 3, 2041
US10383961 Expires Jul 2, 2033
US10159759 Expires Aug 23, 2032
US11160888 Expires Aug 23, 2032

Exclusivity

ODE-317 Until Sep 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.